Press Release
-
EG BioMed Developing a Breast Cancer Monitoring Test Kit
The EG-Breast Blood Test-P1, developed by EG BioMed Co. Ltd., has demonstrated outstanding performance with over 90% sensitivity and accuracy in monitoring disease progression in breast cancer patients during follow-up. This comprehensive study was conducted between 2016 and 2023 in Taipei, Taiwan, and involved over 400 breast cancer patients with follow-up periods ranging from one…
-
EG BioMed Expands into the U.S. Market, Establishes Subsidiary EG BioMed US Inc.
EG BioMed Co., Ltd. from Taiwan is excited to announce that we are establishing a laboratory in Seattle, USA, as part of our efforts to expand into the U.S. market. We are currently preparing to apply for CLIA and Washington State medical test certifications to support our U.S. clinical trials and future FDA applications. Our…
-
EG BioMed’s innovative technology opens a new era of accurate detection of breast cancer!
2022/03/31 Note, according to the statistics of the Ministry of Health and Welfare, “breast cancer” is the number one cancer among women in my country, and the incidence rate is also rising year by year. At present, breast cancer in Taiwan has two warning signs of “invincible and younger”. It can be said to be…